United States · Wires & real time · Bloomberg

Gilead-Backed Aspen Neuroscience Shares Decline 2% After US IPO

Published by Bloomberg · United States 3 h ago

Aspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 2% after raising about $140.6 million in a US initial public offering.

Read the full article on Bloomberg Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.bloomberg.com)

Also worth reading

汽车与娱乐跨界融合：2026 LOS ANGELES AUTO SHOW 带来全新合作、明星活动及更多精彩

Associated Press (Business)

Greenland opens new international airport to lure tourists as it eyes future independence

Nebius Group announces date of third quarter 2026 results and conference call

Dow Jones Newswires

Takeaways from the Inaugural Dow Jones Energy Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows